These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 23438330)

  • 1. Orvinols with mixed kappa/mu opioid receptor agonist activity.
    Greedy BM; Bradbury F; Thomas MP; Grivas K; Cami-Kobeci G; Archambeau A; Bosse K; Clark MJ; Aceto M; Lewis JW; Traynor JR; Husbands SM
    J Med Chem; 2013 Apr; 56(8):3207-16. PubMed ID: 23438330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.
    Harland AA; Yeomans L; Griggs NW; Anand JP; Pogozheva ID; Jutkiewicz EM; Traynor JR; Mosberg HI
    J Med Chem; 2015 Nov; 58(22):8952-69. PubMed ID: 26524472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mixed kappa/mu opioid receptor agonists: the 6 beta-naltrexamines.
    Cami-Kobeci G; Neal AP; Bradbury FA; Purington LC; Aceto MD; Harris LS; Lewis JW; Traynor JR; Husbands SM
    J Med Chem; 2009 Mar; 52(6):1546-52. PubMed ID: 19253970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placement of Hydroxy Moiety on Pendant of Peptidomimetic Scaffold Modulates Mu and Kappa Opioid Receptor Efficacy.
    Harland AA; Pogozheva ID; Griggs NW; Trask TJ; Traynor JR; Mosberg HI
    ACS Chem Neurosci; 2017 Nov; 8(11):2549-2557. PubMed ID: 28796483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors.
    Neumeyer JL; Zhang B; Zhang T; Sromek AW; Knapp BI; Cohen DJ; Bidlack JM
    J Med Chem; 2012 Apr; 55(8):3878-90. PubMed ID: 22439881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.
    Wang Y; Tang K; Inan S; Siebert D; Holzgrabe U; Lee DY; Huang P; Li JG; Cowan A; Liu-Chen LY
    J Pharmacol Exp Ther; 2005 Jan; 312(1):220-30. PubMed ID: 15383632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effects of changes to the chain linking of the C14-amino group to the aryl ring.
    Rennison D; Moynihan H; Traynor JR; Lewis JW; Husbands SM
    J Med Chem; 2006 Oct; 49(20):6104-10. PubMed ID: 17004724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of kappa opioid receptor mediated, dynorphin-stimulated [35S]GTPγS binding in mouse striatum for the evaluation of selective KOR ligands in an endogenous setting.
    Zhou L; Stahl EL; Lovell KM; Frankowski KJ; Prisinzano TE; Aubé J; Bohn LM
    Neuropharmacology; 2015 Dec; 99():131-41. PubMed ID: 26160155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors.
    Olianas MC; Concas D; Onali P
    Br J Pharmacol; 2006 Feb; 147(4):360-70. PubMed ID: 16402046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major effect of pyrrolic N-benzylation in norbinaltorphimine, the selective kappa-opioid receptor antagonist.
    Chauvignac C; Miller CN; Srivastava SK; Lewis JW; Husbands SM; Traynor JR
    J Med Chem; 2005 Mar; 48(5):1676-9. PubMed ID: 15743210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
    Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
    J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, Pharmacology, and Molecular Docking Studies on 6-Desoxo-N-methylmorphinans as Potent μ-Opioid Receptor Agonists.
    Dumitrascuta M; Ben Haddou T; Guerrieri E; Noha SM; Schläfer L; Schmidhammer H; Spetea M
    J Med Chem; 2017 Nov; 60(22):9407-9412. PubMed ID: 29053268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mixed κ/μ partial opioid agonists as potential treatments for cocaine dependence.
    Bidlack JM
    Adv Pharmacol; 2014; 69():387-418. PubMed ID: 24484983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anatomical distribution of mu, delta, and kappa opioid- and nociceptin/orphanin FQ-stimulated [35S]guanylyl-5'-O-(gamma-thio)-triphosphate binding in guinea pig brain.
    Sim LJ; Childers SR
    J Comp Neurol; 1997 Oct; 386(4):562-72. PubMed ID: 9378852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism.
    Husbands SM; Neilan CL; Broadbear J; Grundt P; Breeden S; Aceto MD; Woods JH; Lewis JW; Traynor JR
    Eur J Pharmacol; 2005 Feb; 509(2-3):117-25. PubMed ID: 15733546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes.
    Lester PA; Traynor JR
    Brain Res; 2006 Feb; 1073-1074():290-6. PubMed ID: 16443205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
    Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
    Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?
    Bart G; Schluger JH; Borg L; Ho A; Bidlack JM; Kreek MJ
    Neuropsychopharmacology; 2005 Dec; 30(12):2254-62. PubMed ID: 15988468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-affinity carbamate analogues of morphinan at opioid receptors.
    Peng X; Knapp BI; Bidlack JM; Neumeyer JL
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1508-11. PubMed ID: 17276685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo characterization of (-)(-)MCL-144 and (+)(-)MCL-193: isomeric, bivalent ligands with mu/kappa agonist properties.
    Mathews JL; Fulton BS; Negus SS; Neumeyer JL; Bidlack JM
    Neurochem Res; 2008 Oct; 33(10):2142-50. PubMed ID: 18528756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.